Congress trades
United Therapeutics Corporation (UTHR)
About United Therapeutics Corporation
from the company's filings and listing- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Martine A. Rothblatt
- Employees
- 1,400
- Listed since
- Jun 17, 1999
- Market value
- $21.5B
- Price to earnings
- 16.8
- Earnings per share
- $30.77
- Dividend yield
- -
Earnings
6 reported quarters · next on Nov 4, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 5, 2026 | $7.27 | $6.86 | $783.3M | $804.6M | EPS beatRevenue miss |
| Q1 FY2026reported May 6, 2026 | $5.82 | $7.00 | $781.5M | $797.4M | EPS missRevenue miss |
| Q4 FY2025reported Feb 25, 2026 | $7.70 | $7.13 | $790.2M | $813.1M | EPS beatRevenue miss |
| Q3 FY2025reported Oct 29, 2025 | $7.16 | $6.89 | $799.5M | $814.8M | EPS beatRevenue miss |
| Q2 FY2025reported Jul 30, 2025 | $6.41 | $7.29 | $798.6M | $801.9M | EPS missRevenue in line |
| Q1 FY2025reported Apr 30, 2025 | $6.63 | $6.29 | $794.4M | $778.7M | EPS beatRevenue beat |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for 2025 · proxy filed Apr 29, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Martine RothblattChairperson and Chief Executive Officer | $1.5M | $6.1M | $10.4M | $18.0M |
| Michael BenkowitzPresident and Chief Operating Officer | $1.4M | $3.1M | $9.8M | $14.4M |
| James EdgemondChief Financial Officer and Treasurer | $956K | $2.0M | $5.4M | $8.3M |
| Paul MahonExecutive Vice President and General Counsel | $964K | $1.5M | $3.0M | $5.5M |
The summary compensation table from the 2025 proxy statement, current executives only. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Change | Of company |
|---|---|---|---|---|
| Blackrock, Inc. | $2.9B | 5,294,529 | -1.9% | 12.43% |
| Avoro Capital Advisors LLC | $1.5B | 2,777,777 | +5.6% | 6.52% |
| Vanguard Portfolio Management LLC | $1.0B | 1,919,429 | -4.2% | 4.51% |
| Vanguard Capital Management LLC | $1.0B | 1,918,256 | -2.0% | 4.50% |
| State Street Corp | $1.0B | 1,898,064 | +2.9% | 4.46% |
| Renaissance Technologies LLC | $925.8M | 1,708,739 | -4.4% | 4.01% |
| Wellington Management Group LLP | $747.2M | 1,379,025 | -39.1% | 3.24% |
| Geode Capital Management, LLC | $538.9M | 996,598 | -19.2% | 2.34% |
| Jupiter Topco LLC | $450.1M | 831,129 | +100.0% | 1.95% |
| Norges Bank | $376.4M | 694,753 | +100.0% | 1.63% |
| Assetmark, Inc | $338.1M | 624,068 | +1.3% | 1.46% |
| AQR Capital Management LLC | $294.6M | 546,002 | -33.9% | 1.28% |
A 13F reports long US equity positions 45 days after the quarter ends, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in UTHR
20 disclosures of 46 on record · median 27d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Lisa C. McClainSpouse | Stock | Purchase | $1,001 - $15,000 | +10.8%S&P +12.3% · vs S&P 500 -1.5% | Oct 30, 2025 | Nov 21, 2025 | 22d |
| Lisa C. McClainSpouse | Stock | Sale | $1,001 - $15,000 | +7.5%S&P +13.2% · vs S&P 500 -5.7% | Oct 30, 2025 | Nov 21, 2025 | 22d |
| Lisa C. McClainSpouse | Stock | Sale | $1,001 - $15,000 | +12.8%S&P +12.0% · vs S&P 500 +0.8% | Oct 31, 2025 | Nov 21, 2025 | 21d |
| Michael T. McCaul | Stock | Sale | $15,001 - $50,000 | +19.3%S&P +11.4% · vs S&P 500 +7.9% | Oct 27, 2025 | Nov 10, 2025 | 14d |
| Michael T. McCaul | Stock | Purchase | $50,001 - $100,000 | +67.8%S&P +20.8% · vs S&P 500 +47.0% | Aug 7, 2025 | Sep 11, 2025 | 35d |
| Michael T. McCaul | Stock | Sale | $50,001 - $100,000 | +60.9%S&P +18.3% · vs S&P 500 +42.5% | Aug 22, 2025 | Sep 11, 2025 | 20d |
| Lisa C. McClainSpouseFiled late | Stock | Purchase | $1,001 - $15,000 | +81.7%S&P +27.0% · vs S&P 500 +54.7% | Jun 11, 2025 | Aug 13, 2025 | 63d |
| Michael T. McCaul | Stock | Sale | $100,001 - $250,000 | +76.7%S&P +23.8% · vs S&P 500 +52.9% | Jun 27, 2025 | Jul 7, 2025 | 10d |
| Michael T. McCaul | Stock | Sale | $15,001 - $50,000 | +26.4%S&P +29.2% · vs S&P 500 -2.8% | Nov 6, 2024 | Dec 16, 2024 | 40d |
| Michael T. McCaul | Stock | Sale | $15,001 - $50,000 | +39.2%S&P +29.4% · vs S&P 500 +9.9% | Nov 19, 2024 | Dec 16, 2024 | 27d |
| Michael T. McCaul | Stock | Sale | $250,001 - $500,000 | +39.2%S&P +29.4% · vs S&P 500 +9.9% | Nov 19, 2024 | Dec 16, 2024 | 27d |
| Michael T. McCaul | Stock | Sale | $15,001 - $50,000 | +37.9%S&P +29.3% · vs S&P 500 +8.6% | Nov 20, 2024 | Dec 16, 2024 | 26d |
| Michael T. McCaul | Stock | Sale | $1,001 - $15,000 | +26.4%S&P +29.2% · vs S&P 500 -2.8% | Nov 6, 2024 | Dec 16, 2024 | 40d |
| Michael T. McCaul | Stock | Sale | $100,001 - $250,000 | +37.9%S&P +29.3% · vs S&P 500 +8.6% | Nov 20, 2024 | Dec 16, 2024 | 26d |
| Michael T. McCaul | Stock | Sale | $100,001 - $250,000 | +134.7%S&P +85.6% · vs S&P 500 +49.1% | May 12, 2023 | Jun 22, 2023 | 41d |
| Michael T. McCaul | Stock | Sale | $15,001 - $50,000 | +134.7%S&P +85.6% · vs S&P 500 +49.1% | May 12, 2023 | Jun 22, 2023 | 41d |
| Michael T. McCaulFiled late | Stock | Purchase | $1,001 - $15,000 | +202.3%S&P +77.6% · vs S&P 500 +124.7% | Mar 1, 2022 | Apr 18, 2022 | 48d |
| Michael T. McCaulFiled late | Stock | Purchase | $15,001 - $50,000 | +202.3%S&P +77.6% · vs S&P 500 +124.7% | Mar 1, 2022 | Apr 18, 2022 | 48d |
| Michael T. McCaul | Stock | Sale | $15,001 - $50,000 | +150.0%S&P +72.8% · vs S&P 500 +77.2% | Jan 28, 2022 | Feb 23, 2022 | 26d |
| Michael T. McCaul | Stock | Sale | $1,001 - $15,000 | +150.0%S&P +72.8% · vs S&P 500 +77.2% | Jan 28, 2022 | Feb 23, 2022 | 26d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 9, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Questions
Which members of Congress have traded UTHR?
Lisa C. McClain, Michael T. McCaul disclosed UTHR transactions in the filings shown here.
How quickly are UTHR trades disclosed?
Congressional disclosures took a median of 27 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.